Year in Review

Benefits of Dual I-O Therapy in Metastatic Uveal Melanoma
The combination of nivolumab and ipilimumab offers deep and sustained responses and improved overall survival in malignant uveal melanoma. Read More ›

First-line treatment with relatlimab plus nivolumab demonstrated a statistically significant progression-free survival benefit compared with nivolumab monotherapy in patients with advanced melanoma. Read More ›

In a 6.5-year update of CheckMate-067, durable improvements in overall survival, progression-free survival, and objective response rate were observed with nivolumab plus ipilimumab over nivolumab alone as first-line therapy in patients with advanced melanoma, with no new safety signals. Read More ›

Neoadjuvant and adjuvant treatment with nivolumab plus relatlimab for resectable stage III melanoma achieved high pathologic complete response and major pathologic response rates. Read More ›

Dual Immune Checkpoint Inhibitors in Advanced Cutaneous Melanoma
Dual immunotherapy provides significant and durable benefits as first-line treatment and as neoadjuvant therapy in advanced melanoma. Read More ›

Durvalumab plus either oleclumab or monalizumab improved overall response rate, progression-free survival, and 10-month progression-free survival in locally advanced, unresectable, stage III NSCLC. Read More ›

The phase 3 CheckMate-743 trial demonstrated survival improvement over 3 years with first-line nivolumab plus ipilimumab for patients with unresectable malignant pleural mesothelioma. Read More ›

Benefits of Dual I-O Therapy in NSCLC and Malignant Pleural Mesothelioma
Combinations of novel immunotherapy agents provide benefits over standard-of-care therapy in NSCLC and malignant pleural mesothelioma. Read More ›

Page 6 of 9